Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Conditions:   Advanced Differentiated Thyroid Gland Carcinoma;   Advanced Head and Neck Carcinoma;   Advanced Hepatocellular Carcinoma;   Advanced Kaposi Sarcoma;   Advanced Lung Non-Small Cell Carcinoma;   Advanced Lung Small Cell Carcinoma;   Advanced Malignant Solid Neoplasm;   Advanced Melanoma;   Advanced Ovarian Carcinoma;   Advanced Prostate Carcinoma;   Advanced Renal Cell Carcinoma;   Advanced Thyroid Gland Medullary Carcinoma;   Advanced Urothelial Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Castration-Resistant Prostate Carcinoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   HIV Infection;   Metastatic Differentiated Thyroid Gland Carcinoma;   Metastatic Head and Neck Carcinoma;   Metastatic Hepatocellular Carcinoma;   Metastatic Kaposi Sarcoma;   Metastatic Lung Non-Small Cell Carcinoma;   Metastatic Lung Small Cell Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Melanoma;   Metastatic Ovarian Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Renal Cell Carcinoma;   Metastatic Thyroid Gland Medullary Carcinoma;   Metastatic Triple-Negative Breast Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Differentiated Thyroid Gland Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Kaposi Sarcoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Recurrent Triple-Negative Breast Carcinoma;   Recurrent Urothelial Carcinoma;   Refractory Differentiated Thyroid Gland Carcinoma;   Stage III Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage III Hepatocellular Carcinoma AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage III Renal Cell Cancer AJCC v8;   Stage III Thyroid Gland Medullary Carcinoma AJCC v8;   Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Thyroid Gland Medullary Carcinoma AJCC v8;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Cabozantinib S-malate;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 1, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine